CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), CD20-directed cytolytic effects

Therapeutic Areas

NeoplasmsImmune System DiseasesInfectious Diseases+ [11]

Active Indication

Autoimmune Haemolytic AnaemiasCardiac transplant rejectionLiver transplant rejection+ [143]

Inactive Indication

Acute bilineal leukemiaAcute Graft Versus Host DiseaseAdult Acute Myeloblastic Leukemia+ [147]

Originator Organization

Genentech, Inc.

Active Organization

Celgene Corp.

The University of Texas MD Anderson Cancer Center

Genmab A/S

+ [41]

Inactive Organization

University of California, Davis

University of Nebraska

University of Washington

+ [48]

License Organization

Shanghai Roche Pharmaceuticals Ltd.

IDEC Pharmaceuticals Corp.

Qingdao Baheal Medical, Inc.

+ [4]

Drug Highest PhaseApproved

First Approval Date

United States (26 Nov 1997),

Non-Hodgkin Lymphoma

RegulationOrphan Drug (United States), Orphan Drug (European Union), Orphan Drug (Japan)

Structure/Sequence

Sequence Code 27145L

Source: *****

Sequence Code 83181H

Source: *****

2,656

Clinical Trials associated with Rituximab

NCT07137481

/ Not yet recruitingPhase 2IIT

Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies

To determine the safety and efficacy (1-year PFS) of iC9/CD5CAR/IL-15 NK cells as consolidation in patients with aggressive T-cell malignances in first remission.

Start Date28 Feb 2027

Sponsor / Collaborator

The University of Texas MD Anderson Cancer Center

ACTRN12626000311358

/ Not yet recruitingPhase 3IIT

An ALLG international randomised phase III trial of Surovatamig versus radiotherapy with or without Rituximab in limited stage nodal Follicular Lymphoma

Start Date12 Jan 2027

Sponsor / Collaborator

Australasian Leukaemia & Lymphoma Group

NCT07578077

/ Not yet recruitingPhase 1/2IIT

A Phase 1/2 Study of the CELMoD Agent Golcadomide in Combination With Rituximab in Patients With Relapsed or Refractory Mantle Cell Lymphoma

This phase I/II trial tests the safety, side effects, best dose and effectiveness of golcadomide in combination with rituximab in treating patients with mantle cell lymphoma that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Golcadomide may help block the formation, growth or spread of cancer cells. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving golcadomide in combination with rituximab may better treat patients with relapsed or refractory mantle cell lymphoma.

Start Date21 Dec 2026

Sponsor / Collaborator

City of Hope National Medical Center

[+1]

100 Clinical Results associated with Rituximab

100 Translational Medicine associated with Rituximab

100 Patents (Medical) associated with Rituximab

9,998

Literatures (Medical) associated with Rituximab

31 Dec 2026·mAbs

Impact of afucosylation strategy on antibody function: a comparative study of glycoengineered anti-CD20 antibodies Obinutuzumab and Obinutuzumab beta

Article

Author: Sun, Mingze ; Huang, Shuo ; Shuang, Qing ; Sun, Jicui ; Jiang, Lingling ; Li, Feng ; Shen, Qunfang ; Li, Jiangmei ; Yang, Lijing ; Zhang, Lunfeng ; Chen, Hong ; Lin, Guangzhong

Enhancing antibody-dependent cellular cytotoxicity (ADCC) via N-glycan afucosylation of Asn-297 is a validated strategy to improve the clinical efficacy of therapeutic antibodies. However, the impact of distinct glycoengineering approaches on the function of antibodies has not been systematically elucidated. Here, we experimentally compared two type II anti-CD20 antibodies, Obinutuzumab (Gazyva®) and Obinutuzumab beta (MIL62, Bejescin®), which share identical amino acid sequences but exhibit divergent glycosylation profiles. MIL62 was engineered with complete core afucosylation (fucose < 0.1%) lacking bisecting N-acetylglucosamine (GlcNAc) via knockout of the GDP-fucose transporter (GFT) in Chinese hamster ovary (CHO) cells used to produce the antibody. Conversely, Gazyva was produced in CHO cells that overexpress β-1,4-N-acetylglucosaminyltransferase III (GnT-III) and α-mannosidase II (α-ManII), resulting in ~50% fucose content and >80% bisecting GlcNAc occupancy. These distinct glycoengineering strategies led to disparate functional outcomes: afucosylated MIL62 showed improved FcγRIIIA binding and ADCC potency, while Gazyva with bisecting GlcNAc modifications exhibited higher glycoform heterogeneity and reduced thermal stability. Both antibodies displayed comparable FcRn binding, mannosylation, sialylation, and murine pharmacodynamics, mediating complete depletion of B cells in blood, lymph nodes, and spleen. Upon antigen rechallenge, MIL62 suppressed specific antibody titers, indicating memory B-cell eradication and profound potential to prevent autoimmune relapse. This study demonstrates that distinct glycoengineering strategies fundamentally reshape the antibody glycan profile beyond merely reducing fucose. These structural differences not only fine-tune ADCC potency, but also impact antibody stability. Particularly, complete afucosylation of MIL62 led to optimized ADCC potency and effectively suppressed pathogenic B cells repopulation in a delta-like ligand 3 (DLL3) re-challenge model, providing a critical framework for designing next-generation antibodies with superior therapeutic efficacy.

31 Dec 2026·RENAL FAILURE

Early posttransplant rituximab use in kidney transplant recipients with preexisting donor-specific antibodies

Article

Author: Fornadi, Katalin ; Molnar, Miklos Z. ; Jweehan, Duha ; Yamauchi, Junji ; Marineci, Silviana ; Pole, Ann ; Lazar-Molnar, Eszter ; Raghavan, Divya ; Jain, Dharmendra ; Oygen, Suayp

The presence of pretransplant anti-human leukocyte antigen (HLA) donor-specific antibodies (DSAs) is still a significant barrier to successful kidney transplantation, as it increases the risk of rejection and graft failure. Rituximab (anti-CD20 antibody) has been administered in hopes of suppressing DSA production and rejection in those with preformed DSAs. However, existing studies report conflicting outcomes, underscoring the need for more data to guide clinical practice. Thus, we evaluated the efficacy of early posttransplant rituximab administration in a cohort of kidney transplant recipients with pretransplant anti-HLA DSAs. In this retrospective study of 77 patients, we compared 1-year transplant outcomes between patients treated with and without rituximab for pretransplant anti-HLA DSAs. Infectious complications tended to occur more often in the rituximab group (BK polyomavirus DNAemia >10,000 copies/mL, 3 [19%] vs. 8 [13%]; quantifiable cytomegalovirus DNAemia, 8 [50%] vs. 19 [31%]; infection requiring hospitalization, 5 [31%] vs. 11 [18%]), but none of these differences reached statistical significance. The incidence of biopsy-proven rejection (2 [13%] vs. 12 [20%]) and high plasma donor-derived cell-free DNA (2 [18%] vs. 12 [27%]) tended to be more frequent in the no-rituximab group, but none of these reached statistical significance. Preexisting DSA persisted or recurred in 44% of the patients that received rituximab, and in 46% of patients who did not receive rituximab. Similarly, de novo DSA occurred in 31% of those who received rituximab versus in 25% of those who did not. Rituximab administration did not result difference in graft and patient survival or rejection rates or recurrence of preexisting DSA.

31 Dec 2026·RENAL FAILURE

Long-term real-world outcomes of rituximab in primary membranous nephropathy: a 154-patient cohort study from China

Article

Author: Fang, Ying-xin ; Shang, Wen-ya ; Zheng, Zhen-feng ; Wei, Li ; Cao, Xin ; Jia, Jun-ya ; Zhang, Xin-xin ; Yan, Tie-kun ; Xu, Peng-cheng ; Qi, Yan ; Gao, Xi-qian ; Gu, Qiu-hua ; Cheng, Xi

To investigate the long-term efficacy and safety of rituximab (RTX) in treating patients with primary membranous nephropathy (pMN), a total of 154 patients with pMN receiving RTX treatment were retrospectively enrolled in this study. The study included 92 patients who received RTX as an initial therapy, and 62 patients who received it as an alternative therapy. Over a median follow-up of 30.0 (24.0, 47.0) months after RTX treatment, 102/121 (84.3%) patients achieved immunological remission. And 128/154 (83.1%) patients achieved clinical remission (including 37.7% of CR and 45.5% of PR), accompanied by significant reduction in proteinuria and increase in serum albumin levels. Clinical response rates were comparable between the initial and alternative therapy groups (87.0 vs. 77.4%, p = 0.131), though patients in the alternative therapy group required a longer time to achieve remission. Among the 21 patients with eGFR < 60 mL·min^-1·(1.73 m²)^-1, 12 (57.1%) responded to RTX. Though two patients progressed to end-stage renal disease (ESRD) during follow-up, the remaining 19 patients showed an improvement in eGFR from 48.0 (38.0, 55.0) to 62.0 (36.0, 73.0) mL·min^-1·(1.73 m²)^-1. The clinical response in the RTX monotherapy group did not differ significantly from that in patients who received RTX in combination with glucocorticoids or other immunosuppressive agents. Twenty-eight patients experienced adverse events, most of which were mild and manageable. RTX, utilized as either an initial or alternative therapy, induced a significant clinical response in patients with pMN, including those with compromised renal function. These findings support RTX as an effective and well-tolerated option across various pMN patient profiles.

1,105

News (Medical) associated with Rituximab

09 Jul 2026

·www.biospace.com

Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate

First-of-Kind, Dual-CAR T cell Targeting CD19 and CD38 for Comprehensive Elimination of Complex, Multi-System Autoimmune Disorders Advances into Phase 1/2 Clinical Development Novel 13-point edited CAR T cell Built with a Suite of Genetic Edits and Manufactured as a Uniform Drug Product to Support Clinical Safety and Durable Efficacy in Autoimmune and Hematological Malignancies SAN DIEGO, July 09, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies broadly to patients with cancer and autoimmune disease, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for FT839, the Company’s next-generation, off-the-shelf CAR T-cell product candidate uniquely engineered to co-target CD19 and CD38. With IND clearance, the Company plans to advance FT839 into a basket clinical trial intended to evaluate the product candidate across a range of autoimmune diseases when administered in combination with standard-of-care therapy and without dependence on conditioning chemotherapy. Enrollment in the Phase 1/2 study is expected to commence in the second half of 2026. “FDA clearance of the FT839 IND is an important milestone that expands our off-the-shelf, iPSC-derived CAR T-cell platform capabilities for the comprehensive treatment of autoimmune disease, including rheumatoid arthritis,” said Bob Valamehr, Ph.D., M.B.A., President and Chief Executive Officer of Fate Therapeutics. “By co-targeting CD19 and CD38, FT839 is uniquely engineered to eliminate the full spectrum of aberrant, disease-driving immune cells, including B cells, plasma cells, and activated T cells, that are often the foundation of multicellular disease found in many autoimmune disorders as well as in hematological malignancies. In addition to the incorporation of multiple genetic edits to enhance performance and safety of the drug product, FT839 also includes our patented Sword & Shield™ technology which is designed to support durable activity without dependence on conditioning chemotherapy. The remarkably homogenous pro FT839, a 13-point edited CAR T cell, is a testament to our distinct ability to genetically engineer cells and is enabled by our iPSC master cell bank platform where we have pioneered the ability to manufacture multiplex-engineered CAR T cells in a uniform and consistent manner at large scale for on-demand availability. We look forward to initiating the basket portion of this exciting Phase 1/2 study across multiple autoimmune indications and to advancing a truly accessible treatment option for patients in need.” FT839 is the Company’s second CAR T-cell product candidate to advance into clinical development for autoimmune disease, joining FT819, an off-the-shelf, CD19-targeted CAR T-cell candidate currently entering Phase 2 development in a potentially registrational trial in lupus nephritis. FT839 is designed to broaden the reach of off-the-shelf CAR T-cell therapy beyond B-cell depletion by simultaneously targeting CD19 and CD38. The elimination of B-lineage cells, including plasma cells, and CD38-expressing activated and proliferating immune cells (e.g. T cells, macrophages and NK cells) is expected to support comprehensive immune rebalancing across a diverse spectrum of autoimmune conditions. FT839 immune cell targeting can be further extended in combination with approved therapeutic monoclonal antibodies or T-cell engagers. Additionally, the Phase 1/2 trial design allows for accelerated development opportunities by avoiding the gap between separate Phase 1 and Phase 2 trials and is intended to enable assessment of both safety and efficacy data in a single trial. FT839 has been engineered with 13 targeted genetic edits that together confer multi-antigen targeting, immune evasion, and enhanced functional persistence, and that are designed to overcome key limitations of autologous patient-derived and allogeneic donor-derived CAR T-cell therapy, including manufacturing complexity, high cost, limited on-demand availability, and the requirement for intensive conditioning chemotherapy. Analogous to master cell banks used to mass produce biopharmaceutical drug products such as monoclonal antibodies, a precisely engineered clonal master iPSC bank serves as the starting cell source to manufacture FT839, overcoming numerous limitations associated with patient- and donor-sourced CAR T-cell therapies. FT839 is well-defined and uniform in composition, produced at a low cost of goods, and can be stored in inventory for off-the-shelf, on-demand availability to enable access for a broad patient population. FT839 multiplexed engineering includes the following functional elements: Dual CD19 and CD38 chimeric antigen receptors (CARs) to eliminate aberrant and pathogenic immune cells such as B cells, plasma cells, macrophages and activated T cells, as well as hematologic cancer cells of lymphoma, leukemia, and myeloma origin. High-affinity, non-cleavable CD16 (hnCD16) Fc receptor to maximize antibody-dependent cellular cytotoxicity (ADCC) in combination with approved therapeutic monoclonal antibodies (for example, rituximab or obinutuzumab), extending coverage against antigen-heterogeneous and antigen-escape populations. CD3ε Fusion Receptor (CD3FR) to support T-cell engager (TCE)–driven activation in combination with approved bispecific engagers (for example, epcoritamab, teclistamab or talquetamab). Sword & Shield™ technology (comprising an Alloimmune Defense Receptor and a CD58 genetic knockout) to selectively eliminate and evade host allogeneic immune responses, promote functional persistence, and thereby avoid the need for conditioning chemotherapy. Synthetic chemokine receptor CXCR2 and a TGFβ signal redirection receptor (TGFβ SRR) to improve trafficking to sites of pathological activity and to counter the immunosuppressive effects of the tissue microenvironment. CD38 and TRAC genetic knockouts to enhance metabolic fitness and safety pro avoiding the risk of graft versus host disease in allogeneic setting, respectively. In preclinical studies, including data presented at the 2026 American Society of Gene and Cell Therapy (ASGCT) and at the European Congress of Rheumatology (EULAR) Annual Meetings, FT839 selectively eliminated autoimmune disease drivers such as B cells, plasma cells, and activated T cells, as well as hematologic cancer cells, both as monotherapy through its dual CARs and in combination with therapeutic monoclonal antibodies and T-cell engagers. In allogeneic settings, Sword & Shield™ technology supported enhanced persistence and durable activity of FT839 without conditioning chemotherapy. The Phase 1/2 study consists of a multi-indication basket trial designed to evaluate the safety, tolerability, and preliminary activity of FT839 administered in combination with standard-of-care therapy, with or without the use of conditioning chemotherapy, in patients with autoimmune disease. The initial autoimmune indications to be evaluated in the trial are: Rheumatoid arthritis, ANCA-associated vasculitis, Idiopathic inflammatory myositis, Systemic lupus erythematosus with or without nephritis, and Systemic sclerosis. The company also plans to investigate the activity of FT839 in other autoimmune diseases, including Type 1 diabetes and multiple sclerosis, through investigator-initiated trials. Beyond autoimmune disease, the Company believes the dual-CAR mechanism of FT839 and ability to combine with therapeutic monoclonal antibodies and T-cell engagers also support its potential in hematologic malignancies, including B-cell lymphomas, leukemias, and multiple myeloma. About FT839 FT839 is the Company’s first multi-antigen dual-CAR T-cell product candidate that is designed to express two unique CARs: a first CAR targeting the B-cell lineage marker CD19 and the second CAR targeting the immune activation marker CD38, which is often found on aberrant T, NK and B cells. FT839 is the second product candidate to contain the Company’s Sword and Shield TM technology. At the 2025 ASH Annual Meeting, the Company presented preclinical data demonstrating the ability of FT839, with its dual-CAR mechanism and unique ability to synergize with monoclonal antibodies and T-cell engagers through its incorporated hnCD16 Fc receptor and CD3 fusion receptor, respectively, to specifically eliminate a variety of pathogenic immune cell types without requiring conditioning chemotherapy, suggesting its potential to broadly treat complex autoimmune diseases and hematologic malignancies. About Fate Therapeutics, Inc. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit Forward-Looking Statements This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the Company's product candidates, clinical studies and preclinical research and development programs, the Company’s progress, plans and timelines for the clinical investigation of its product candidates, including the Company’s plans to complete IND-enabling activities and submit IND applications for its product candidates, the initiation and continuation of enrollment in the Company’s clinical trials, the initiation of additional clinical trials, including in new indications, and additional dose cohorts in ongoing clinical trials of the Company’s product candidates, the availability of data from the Company’s clinical trials and the Company’s plans to provide updates on its clinical trials, the clinical, therapeutic and market potential of the Company’s research and development programs and product candidates, the Company’s clinical and product development strategy, and the Company’s progress and plans relating to, and the anticipated timing and outcome of, interactions with the FDA and other regulatory authorities, including its expectations relating to alignment with regulatory authorities on potential registrational pathways for FT839 and FT819. These and any other forward-looking statements in this release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the Company’s research and development programs and product candidates, including those product candidates in clinical investigation, may not demonstrate the requisite safety, efficacy, or other attributes to warrant further development or to achieve regulatory approval, the risk that results observed in prior studies of the Company’s product candidates, including preclinical studies and clinical trials, will not be observed in ongoing or future studies involving these product candidates, the risk of a delay or difficulties in the manufacturing of the Company’s product candidates or in the initiation and conduct of, or enrollment of patients in, any clinical trials, the risk that the Company may cease or delay preclinical or clinical development of any of its product candidates for a variety of reasons (including requirements that may be imposed by regulatory authorities on the initiation or conduct of clinical trials, changes in the therapeutic, regulatory, or competitive landscape for which the Company’s product candidates are being developed, the amount and type of data to be generated or otherwise to support regulatory approval, difficulties or delays in patient enrollment and continuation in the Company’s ongoing and planned clinical trials, difficulties in manufacturing or supplying the Company’s product candidates for clinical testing, failure to demonstrate that a product candidate has the requisite safety, efficacy, or other attributes to warrant further development, and any adverse events or other negative results that may be observed during preclinical or clinical development), the risk that its product candidates may not produce therapeutic benefits or may cause other unanticipated adverse effects, and risks relating to regulatory interactions and the outcome of such interactions. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the Company’s periodic filings with the Securities and Exchange Commission, including but not limited to the Company’s most recently filed periodic report, and from time to time in the Company’s press releases and other investor communications. Fate Therapeutics is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise. Ryan Douglas Fate Therapeutics, Inc. IR@fatetherapeutics.com

ImmunotherapyCell TherapyIND

08 Jul 2026

·www.biospace.com

TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia

Phase 2 trial to evaluate the effects of B-cell depletion with BRIUMVI in approximately 60 patients with treatment-resistant schizophrenia based on emerging evidence linking immune dysfunction to disease in a subset of patients July 06, 2026 -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the initiation of a Phase 2 clinical trial evaluating BRIUMVI® (ublituximab-xiiy), in adults with treatment-resistant schizophrenia. The Phase 2 study is an open-label trial designed to evaluate the efficacy and safety of BRIUMVI in approximately 60 adults with schizophrenia who continue to experience significant symptoms despite receiving standard-of-care antipsychotic treatment. Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics, stated, “The initiation of this Phase 2 study represents an exciting step in exploring the potential role of B-cell depletion in schizophrenia. There is emerging scientific evidence suggesting that immune system dysfunction and neuroinflammation may play a role in the pathophysiology of schizophrenia in a subset of patients. This scientific rationale is further supported by encouraging preliminary clinical findings with rituximab in a small cohort of patients with treatment-resistant schizophrenia, supporting further investigation of B-cell depletion in this condition. Given BRIUMVI’s demonstrated ability to rapidly and efficiently deplete B cells and its established safety profile, we believe it is a compelling candidate to explore in this setting. This study is designed to determine whether B-cell depletion with BRIUMVI can improve symptoms in patients with treatment-resistant schizophrenia and, if successful, could expand the potential utility of BRIUMVI into a significant area of unmet medical need. We look forward to sharing results as they become available.” The Phase 2 study is an open-label, single-arm, multicenter trial evaluating the efficacy and safety of BRIUMVI (ublituximab-xiiy) in adults with treatment-resistant schizophrenia. Approximately 60 participants between the ages of 18 and 60 years are expected to be enrolled. Participants will receive intravenous BRIUMVI and remain on background standard-of-care antipsychotic therapy throughout the study. The primary endpoint is the proportion of participants achieving at least a 20% reduction from baseline in PANSS total score at Week 12, a commonly used threshold for clinical response in schizophrenia studies. Secondary endpoints include additional standard efficacy assessments as well as safety and tolerability. Schizophrenia is a chronic and severe psychiatric disorder characterized by disruptions in thought, perception, emotion, and behavior. Symptoms may include hallucinations, delusions, disorganized thinking, and cognitive impairment, often resulting in significant functional disability. While available antipsychotic therapies can help manage symptoms, many patients continue to experience persistent symptoms despite treatment, highlighting the need for new therapeutic approaches. Emerging research has suggested a potential role for immune dysregulation and neuroinflammatory pathways in the pathophysiology of schizophrenia in some patients, though the clinical relevance of these findings remains under investigation. BRIUMVI is a novel monoclonal antibody that targets a unique epitope on CD20-expressing B-cells. Targeting CD20 using monoclonal antibodies has proven to be an important therapeutic approach for the management of autoimmune disorders, such as RMS. BRIUMVI is uniquely designed to lack certain sugar molecules normally expressed on the antibody. Removal of these sugar molecules, a process called glycoengineering, allows for efficient B-cell depletion at low doses. BRIUMVI is indicated in the U.S. for the treatment of adults with RMS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease and in several countries outside of the U.S. for the treatment of adult patients with RMS with active disease defined by clinical or imaging features. BRIUMVI Patient Support is a flexible program designed by TG Therapeutics to support U.S. patients through their treatment journey in a way that works best for them. TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval by several foreign nations for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. The content above comes from the network. if any infringement, please contact us to modify.

Drug ApprovalClinical ResultVaccine

07 Jul 2026

·www.pharmaceutical-technology.com

EC approves AbbVie’s Tepkinly combination for follicular lymphoma

Epcoritamab is co-developed by AbbVie and Genmab. Credit: © AbbVie Inc. All rights reserved. The European Commission (EC) has granted marketing authorisation for AbbVie’s Tepkinly (epcoritamab) in combination with lenalidomide and rituximab (Tepkinly + R²) for adult patients with relapsed or refractory follicular lymphoma. The decision is based on data from the pivotal Phase III EPCORE FL-1 trial, which assessed the efficacy and safety of the fixed-duration Tepkinly plus lenalidomide and rituximab regimen compared to the standard R² treatment. These results showed that the combination reduced the risk of disease progression or death by 79% versus R² alone. Patients treated with the Tepkinly-based therapy achieved an overall response rate of 96%, compared to 81% for those receiving R². Complete response (CR) rates reached 74% for patients receiving the combination, with 181 out of 243 patients achieving this outcome. For those treated with R² alone, the CR rate was 43%, with 106 out of 245 patients achieving a CR. The safety profile observed in the trial was consistent with the known characteristics of the individual treatments. The most frequent adverse reactions, occurring in 20% or more of patients, included anaemia, constipation, Covid-19, cytokine release syndrome (CRS), diarrhoea, fever, hypogammaglobulinaemia, neutropenia, pneumonia and thrombocytopenia. Serious adverse reactions were reported in 44% of patients receiving the combination. CRS, pneumonia, Covid-19, and febrile neutropenia were among the events affecting at least 5% of participants. AbbVie research and development executive vice-president and chief scientific officer Roopal Thakkar said: “This approval is important because it brings an effective treatment option to patients across Europe, representing meaningful progress for patients with follicular lymphoma.” Epcoritamab is a subcutaneous IgG1-bispecific antibody developed using Genmab’s DuoBody technology. It is being co-developed by AbbVie and Genmab and is approved for certain lymphoma indications in more than 65 territories, under the names Epkinly in Japan and the US, and Tepkinly in the European Union. The companies are investigating further uses of epcoritamab, alone and in combination, for various haematological malignancies in clinical trials. Last month, AbbVie agreed to acquire Apogee Therapeutics for $10.9bn, potentially further fortifying its legacy in the immunology space and marking another sizeable investment into the disease area as it garners notable big pharma interest.

100 Deals associated with Rituximab

External Link

KEGG	Wiki	ATC	Drug Bank
D02994	Rituximab	L01XC02	DB00073

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Autoimmune Haemolytic Anaemias	Japan	Zenyaku Kogyo Co., Ltd.	19 Feb 2026
Cardiac transplant rejection	Japan	Zenyaku Kogyo Co., Ltd.	22 Dec 2023
Liver transplant rejection	Japan	Zenyaku Kogyo Co., Ltd.	22 Dec 2023
Lung transplant rejection	Japan	Zenyaku Kogyo Co., Ltd.	22 Dec 2023
Rejection of pancreas transplant	Japan	Zenyaku Kogyo Co., Ltd.	22 Dec 2023
Renal transplant rejection	Japan	Zenyaku Kogyo Co., Ltd.	22 Dec 2023
Small intestine transplantation rejection	Japan	Zenyaku Kogyo Co., Ltd.	22 Dec 2023
Lupus Nephritis	Japan	Zenyaku Kogyo Co., Ltd.	23 Aug 2023
Neuromyelitis Optica	Japan	Zenyaku Kogyo Co., Ltd.	20 Jun 2022
Pemphigus and Fogo Selvagem	Japan	Zenyaku Kogyo Co., Ltd.	24 Dec 2021
Pemphigus Vulgaris, Familial	Japan	Zenyaku Kogyo Co., Ltd.	24 Dec 2021
Thrombotic Thrombocytopenic Purpura, Acquired	Japan	Zenyaku Kogyo Co., Ltd.	21 Feb 2020
CD20 Positive B-Cell Chronic Lymphocytic Leukemia	Japan	Zenyaku Kogyo Co., Ltd.	26 Mar 2019
Lymphoid Leukemia	Japan	Genentech, Inc.	26 Mar 2019
Lymphoid Leukemia	Japan	IDEC Pharmaceuticals Corp.	26 Mar 2019
Chronic idiopathic thrombocytopenic purpura	Japan	Zenyaku Kogyo Co., Ltd.	26 Jun 2017
Purpura, Thrombocytopenic	Japan	Genentech, Inc.	26 Jun 2017
Purpura, Thrombocytopenic	Japan	IDEC Pharmaceuticals Corp.	26 Jun 2017
Nephrotic Syndrome	Japan	Zenyaku Kogyo Co., Ltd.	29 Aug 2014
Nephrotic Syndrome	Japan	Genentech, Inc.	29 Aug 2014

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Refractory Grade 3a Follicular Lymphoma	Phase 3	United States	Genmab A/S	05 Feb 2024
Refractory Grade 3a Follicular Lymphoma	Phase 3	China	Genmab A/S	05 Feb 2024
Refractory Grade 3a Follicular Lymphoma	Phase 3	Japan	Genmab A/S	05 Feb 2024
Refractory Grade 3a Follicular Lymphoma	Phase 3	Australia	Genmab A/S	05 Feb 2024
Refractory Grade 3a Follicular Lymphoma	Phase 3	Belgium	Genmab A/S	05 Feb 2024
Refractory Grade 3a Follicular Lymphoma	Phase 3	Brazil	Genmab A/S	05 Feb 2024
Refractory Grade 3a Follicular Lymphoma	Phase 3	Bulgaria	Genmab A/S	05 Feb 2024
Refractory Grade 3a Follicular Lymphoma	Phase 3	Canada	Genmab A/S	05 Feb 2024
Refractory Grade 3a Follicular Lymphoma	Phase 3	Croatia	Genmab A/S	05 Feb 2024
Refractory Grade 3a Follicular Lymphoma	Phase 3	Czechia	Genmab A/S	05 Feb 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03054896 (CRC-043 \| phase 2, CTgov)	Phase 2	Richter's syndrome	69	Etoposide+Cyclophosphamide+Pegfilgrastim+Prednisone+Venetoclax+Doxorubicin+Rituximab+Vincristine (VR-EPOCH (Cohort 1))	wuxvckpvyg = nqnfopzgbi nnhpcltbny (mtyhnhcxcs, rnjemnaiea - hjnxgefufw) View more	-	10 Jul 2026
				cyclophosphamide+prednisone+Venetoclax+doxorubicin+Vincristine Sulfate+rituximab (VR-CHOP (Cohort 2))	wuxvckpvyg = akvednxlds nnhpcltbny (mtyhnhcxcs, znicnfncvc - uissvqvdzi) View more
NCT05533125 (REDUCE PMR 1, EULAR2026)	Phase 3	Polymyalgia Rheumatica	110	Rituximab	fccmwsppht(woupohqzkr) = yxtqdbppfn kguzmumnwe (rkldlotdul ) View more	Negative	11 Jun 2026
				Placebo	fccmwsppht(woupohqzkr) = svkwtdhdkp kguzmumnwe (rkldlotdul ) View more
EULAR2026	Not Applicable	Antisynthetase Syndrome	15	Rituximab	pxqvupkzkv(gqdzpapnkz) = adypzejiut xsfnjlcrbq (vvykkgqpkq )	Positive	11 Jun 2026
NCT02631538 (EULAR2026)	Phase 2	Sjogren's Syndrome gene expression signatures	37	Rituximab (RTX)	tapxjqjozb(lcvbyzwels) = nxwdzmtxhy yjlcpvtswm (ldeiiybprc )	Positive	11 Jun 2026
EULAR2026	Not Applicable	Rheumatoid Arthritis	34	Rituximab 200 mg	onbjckvdzi(tikdtgghai) = pwafmegjvm sifbhkiysx (kbnefebazk ) View more	Positive	11 Jun 2026
EULAR2026	Not Applicable	Idiopathic Inflammatory Myopathies	44	Rituximab	sfynuszzue(iytdacplry) = cgszfrpdtp hkwhalgkhe (odvfpuyavd ) View more	Positive	11 Jun 2026
EULAR2026	Not Applicable	Lupus Erythematosus	176	Rituximab	szmigsjije(lqfrehqdnr) = Drug survival was similar for first-line users, but second-line belimumab users had higher drug survival compared with rituximab (HR 1.34, 95% CI 1.02-1.77) kbffuhdret (kpgstoaovq ) View more	Positive	11 Jun 2026
				Belimumab
EULAR2026	Not Applicable	Rheumatoid Arthritis	769	Rituximab (Rheumatoid Arthritis)	atrqcjgygn(whtozewkwp) = rkgpdfnsay shtdgsmcwb (gnokhekunf ) View more	Positive	11 Jun 2026
EULAR2026	Not Applicable	Antisynthetase Syndrome	187	Rituximab ± any DMARD	zuodybsvbs(ligkekaqmj) = uemwkklwkh qhwxfcssqh (erftbjchqa ) View more	Positive	11 Jun 2026
				Cyclophosphamide ± any DMARD	zuodybsvbs(ligkekaqmj) = dvtmupfbag qhwxfcssqh (erftbjchqa ) View more
EULAR2026	Not Applicable	Immunoglobulin G4-Related Disease	167	Rituximab ± glucocorticoids	yeqhvrhvpj(otxjfasugl) = bpusxotzbd ylsndbjzmx (pumcyjbbzb ) View more	Positive	11 Jun 2026
				Glucocorticoids ± non-rituximab immunosuppressant	yeqhvrhvpj(otxjfasugl) = ddomnvxnau ylsndbjzmx (pumcyjbbzb ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis